天美传媒

Dr. Robert Lanford, PhD, is currently the Director of the Southwest National Primate Research Center, one of seven NIH National Primate Research Centers. He is a Scientist at the Texas Biomedical Research Institute and an Adjunct Professor at the University of Texas Health Science Center. Dr. Robert E. Lanford received a B.S. degree from the University of Texas at Arlington in 1974 and a Ph.D. in Virology from Baylor College of Medicine in 1979. He served as Assistant Professor at Baylor College of Medicine until 1984 when he moved to the Southwest Foundation for Biomedical Research (now Texas Biomedical Research Institute) to initiate programs on the use of nonhuman primates as models for human hepatitis infections. Dr. Lanford has published over 170 scientific papers and serves as a reviewer for several journals. His laboratory performs research on multiple hepatitis viruses HAV, HBV, HCV and GBV-B. One of the primary goals of his research program is to better understand the interactions of the virus with the host, and how these interactions influence either viral clearance or persistence and disease progression. His studies in the chimpanzee were the first to use total genome microarray analysis to examine viral-host interactions and the innate immune response to HCV. In collaboration with pharmaceutical companies, he has utilized the chimpanzee model of chronic HBV and HCV infections to evaluate efficacy of new antiviral therapies as the last preclinical step prior to human clinical trials. These studies contributed to the development of cocktails of antivirals that can now cure HCV infection in 12 weeks. Recently, Dr. Lanford has developed a primate model for liver cancer by the genetic engineering of primary baboon hepatocytes with activated baboon oncogenes and autologous transplantation of the cells to the liver of the immunocompetent hepatocyte donor. Efforts are ongoing in his laboratory to develop new nonhuman primate models for HBV research.

Anurag Maheshwari, M.D., specializes in liver disease at The Center for Liver and Hepatobiliary Diseases, part of The Melissa L. Posner Institute for Digestive Health & Liver Disease at Mercy in Baltimore, Maryland. His expertise helps patients seeking focused care for medical conditions of the liver. 

Dr. Anurag Maheshwari provides experience in treating a range of concerns involving the liver including hepatitis, liver cancer, cirrhosis and bile duct conditions.

Dr. Maheshwari cares for patients in need of liver transplants and assists in pre- and post-operative transplant medical care, providing each patient individualized attention, coordination with liver transplant centers, and understanding as they progress toward recovery. Working with international authority Dr. Paul Thuluvath, Dr. Anurag Maheshwari is one of the physicians of The Institute for Digestive Health & Liver Disease at Mercy leading the way in the diagnosis and treatment of liver diseases.

Dr. Anurag Maheshwari works collaboratively with the specialists of The Institute for Cancer Care at Mercy, The Center for Minimally Invasive Surgery at Mercy, The Center for Interventional Pain Medicine at Mercy, The Lung Center at Mercy, and the Division of Interventional Radiology. This comprehensive approach to diagnosis and treatment of digestive tract diseases and the expertise of our doctors makes The Institute for Digestive Health & Liver Disease at Mercy one of the best in Baltimore and the Mid-Atlantic region.

Dr. Maheshwari has been named a "Top Doctor" in Gastroenterology/Liver Disease by Baltimore magazine.

Dr. Anurag Maheshwari is active in advanced research projects in liver diseases. He has authored many peer-reviewed publications and book chapters on issues in liver disease. Dr. Anurag Maheshwari is an active speaker and has appeared at conferences and hospital grand rounds around the country. He has been published in:

American Journal of Gastroenterology
Digestive Diseases and Sciences
Gastroenterology
Hepatology
Lancet
Liver Transplantation
Shakelford鈥檚 Surgery of the Alimentary Tract

Paul J. Thuluvath, M.D., Chief, Division of Gastroenterology at Mercy Medical Center, and Medical Director for The Melissa L. Posner Institute for Digestive Health & Liver Disease at Mercy leads a top rated physician team of gastroenterology specialists in Baltimore, Maryland, who help patients find the best treatment options for digestive diseases and liver conditions.

As the leader of The Center for Liver and Hepatobiliary Diseases, Dr. Paul Thuluvath provides patients with pioneering treatments and advanced technology to help them manage their illness. He is a recognized national and international authority in liver and biliary diseases and dedicated to medical research and clinical trials that are advancing treatment possibilities for patients. While his patients respect his expertise, they value his bedside concern, empathy and personal care that keeps them encouraged. He welcomes patient questions and family involvement, and is devoted to patient education in the healing process.

Dr. Thuluvath and his team of gastroenterology specialists provide expertise, comprehensive care, advanced facilities for endoscopy procedures and leading edge technology, treatment and pioneering medical research.

Dr. Paul Thuluvath coordinates patient care, when needed, working in collaboration with the specialists of The Institute for Cancer Care at Mercy, The Center for Minimally Invasive Surgery at Mercy, The Center for Interventional Pain Medicine at Mercy, The Lung Center at Mercy, and the Division of Interventional Radiology. This comprehensive approach to diagnosis and treatment of digestive health and liver disease and the expertise of our doctors makes The Institute for Digestive Health and Liver Disease at Mercy a leader in the Mid-Atlantic region.

Authority in Liver and Biliary Diseases

Dr. Paul Thuluvath is a known authority in liver and biliary diseases and pre-and post-liver transplant management. He serves on the Editorial Board for: Hepatology, Liver Transplant, and Gastrointestinal Endoscopy. 

He is a frequent speaker and lecturer at national and international meetings on issues in liver and biliary diseases and has addressed medical groups in China, Germany, India, London, Oman, Philippines, Singapore and the United States.

Dr. Adey Nyamathi is a highly respected researcher, academician, and a distinguished professor. Dr. Nyamathi has been the principal investigator in nine NIH-funded RO1s and other NIH grants funded by NIDA, NIAAA, NICHD, NIAID, and NIMHD. During her over three decades of continuous RO1 NIH funding as a Principle Investigator, Dr. Nyamathi has conducted descriptive and randomized trials among vulnerable populations, including homeless, drug-addicted and incarcerated persons, gay/bisexual youth, men at risk for HIV/AIDS, and rural women living with AIDS in India. In her completing NIH-funded study with homeless adults diagnosed with LTBI, Dr. Nyamathi and her team have successfully ensured that 92% of homeless adults in the study have competed their prescribed 3 month treatment. Dr Nyamathi and her team are embarking now on newly funded studies related to HCV and COVID-19.